Lung cancer is the leading cause of cancer death worldwide. Despite the introduction of
more-effective chemotherapeutic agents, it appears that a survival plateau has been …

Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …

Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …

The discovery of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor
receptor (EGFR) and the positive results of the National Cancer Institute of Canada Clinical …

In 2004, several investigators reported that somatic mutations in the epidermal growth factor
receptor gene were associated with clinical responses to erlotinib and gefitinib in patients …

7575 Background: Phase II study showed first-line erlotinib (Erl) produced promising efficacy
in advance NSCLC pts with EGFR Muts. This phase III trial compared PFS and safety of first …

Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …

Purpose This study aimed to assess the incidence of mutations in the epidermal growth
factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients in the Galician …

Background: The effective targeted therapy for lung squamous cell carcinoma (SCC) is
needed. The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The …